

## Submission Data File

General Information	
Form Type*	6-K
Contact Name	M2 Compliance
Contact Phone	754-243-5120
<b>Filer File Number</b>	
Filer CIK*	0001849296
Filer CCC*	*****
Confirming Copy	No
Notify via Website only	No
Return Copy	Yes
SROS*	NONE
Period*	
(End General Information)	

Document Information	
File Count*	2
Document Name 1*	form6-k.htm
Document Type 1*	6-K
<b>Document Description 1</b>	
Document Name 2*	ex99-1.htm
Document Type 2*	EX-99.1
<b>Document Description 2</b>	
(End Document Information)	

Notifications	
Notify via Website only	No
E-mail 1	filing@m2compliance.com
(End Notifications)	

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 6-K**

---

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

September 2022

---

Commission File Number: 001-41386

---

**OKYO Pharma LTD**

(Exact Name of Registrant as Specified in Its Charter)

---

9<sup>th</sup> Floor  
107 Cheapside  
London  
EC2V 6DN

(Address of registrant's principal executive office)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On September 8, 2022, OKYO Pharma LTD (the “Company”) issued a news service announcement in the United Kingdom announcing an Interview is to Air on Bloomberg U.S. on the RedChip Money Report® .

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**OKYO Pharma LTD**

Date: September 8, 2022

By: */s/ Gary Jacob*

Name: Gary Jacob

Title: Chief Executive Officer

EXHIBIT INDEX

**Exhibit  
No.**

**Description**

---

99.1 [News Service Announcement, dated September 8, 2022](#)

---

**Exhibit 99.1****OKYO Pharma Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®**

New York and London– September 8, 2022 – OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and ocular pain, today announces that an interview with its CEO, Dr Gary Jacob will air on The RedChip Money Report® on Bloomberg TV, this Saturday, September 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.

**Interview highlights:**

In the exclusive RedChip Money Report interview, Dr. Gary Jacob discusses the Company’s NASDAQ listing, near term plans for the Phase 2 study for Dry Eye Disease, top-line data expectations, and much more.

Access this interview in its entirety at [https://www.okyoinfo.com/interview\\_access](https://www.okyoinfo.com/interview_access)

A replay will be available in the Investor Updates section of the Company’s website [here](#):

**About OKYO Pharma Limited**

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.

For further information, please visit [www.okyopharma.com/](http://www.okyopharma.com/)

**About The RedChip Money Report®**

The RedChip Money Report® is produced by RedChip Companies Inc., an international Investor Relations and media firm with 30 years’ experience focused on *Discovering Tomorrow’s Blue Chips Today*™. “The RedChip Money Report®” delivers insightful commentary on small cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

**Forward Looking Statements**

Certain statements made in this announcement are forward-looking statements including with respect to the creation of a trading market for ADSs representing the Ordinary Shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including market conditions. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

**Contact:**

OKYO Pharma Limited  
Gary S. Jacob, Ph.D., Chief Executive Officer  
Phone: (212) 209-3998

Dave Gentry  
RedChip Companies Inc.  
1-800-RED-CHIP (733-2447)  
Or 407-491-4498  
[OKYO@redchip.com](mailto:OKYO@redchip.com)

---